Banking & Finance  June 23, 2015

Biodesix adds $11M to Series E funding round

BOULDER — Diagnostic test-maker Biodesix Inc. announced Tuesday that it has raised $11 million through a follow-on sale of preferred shares to existing shareholders.

The Boulder-based company has raised $38 million from 2013 through 2015 by selling series E shares.

The investment will be used for ongoing new product development, expansion of commercial efforts to support Biodesix’ commercialized products VeriStrat and GeneStrat, as well as new product launches scheduled to launch later this year and 2016.

SPONSORED CONTENT

Ways to thank a caregiver

If you have a caregiver or know someone who has been serving as a primary caregiver, March 3rd is the day to reach out and show them how much they are valued!

VeriStrat is a blood-based serum protein test that provides information on disease aggressiveness and helps physicians guide therapy for patients with advanced non-small cell lung cancer.

GeneStrat is a targeted, blood-based mutation test for patients with advanced cancer.

“Biodesix is continuing to focus on advancing the standard of care in cancer by developing and commercializing blood-based diagnostic tests that advance precision medicine — treating the right patient at the right time with the right combination of therapies,” David Brunel, Biodesix’s chief executive, said in a prepared statement. “Securing this investment enables us to continue work on diagnostics that help inform treatment decisions and improve patient care in a cost-effective manner.”

In addition to developing diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve their therapeutic agents.

BOULDER — Diagnostic test-maker Biodesix Inc. announced Tuesday that it has raised $11 million through a follow-on sale of preferred shares to existing shareholders.

The Boulder-based company has raised $38 million from 2013 through 2015 by selling series E shares.

The investment will be used for ongoing new product development, expansion of commercial efforts to support Biodesix’ commercialized products VeriStrat and GeneStrat, as well as new product launches scheduled to launch later this year and 2016.

VeriStrat is a blood-based serum protein test that provides information on disease aggressiveness and helps physicians guide therapy for patients with advanced non-small cell lung cancer.

GeneStrat is a targeted,…

Sign up for BizWest Daily Alerts